Loading
HKSEHealthcareBiotechnology
Latest quote
HK$1.18
−HK$0.08 · -6.35%
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Latest quote
HK$1.18
−HK$0.08 · -6.35%
Regular session · HKT · Market data may be delayed.
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Day range
Current HK$1.18
52-week range
Current HK$1.18
Regular session · HKT · Market data may be delayed.
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Day range
Current HK$1.18
52-week range
Current HK$1.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (HKD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 256.69M HKD | 254.91M HKD | 259.86M HKD | 250.36M HKD | 184.44M HKD |
| Cost of goods sold | 187.49M HKD | 185.1M HKD | 181.46M HKD | 161.17M HKD | 117.74M HKD |
| Gross profit | 69.2M HKD | 69.81M HKD | 78.39M HKD | 89.19M HKD | 66.7M HKD |
| Research and development | 4.3M HKD | 5.59M HKD | 6.04M HKD | 3.88M HKD | 2.43M HKD |
| Selling, general, and administrative | 48.84M HKD | 55.54M HKD | 52.73M HKD | 51.63M HKD | 38.44M HKD |
| Operating expenses | 53.14M HKD | 60.47M HKD | 58.19M HKD | 55.64M HKD | 41.4M HKD |
| Interest income | 289.43K HKD | 812K HKD | 1.76M HKD | 498K HKD | 1.89M HKD |
| Interest expense | 7.56M HKD | 9.56M HKD | 7.07M HKD | 3.95M HKD | 2.58M HKD |
| Depreciation and amortization | 25.81M HKD | 27.49M HKD | 24.81M HKD | 20.55M HKD | 17.26M HKD |
| Operating income | 16.06M HKD | 9.34M HKD | 20.21M HKD | 33.55M HKD | 25.3M HKD |
| Net income | 6.79M HKD | 791K HKD | 10.81M HKD | 25.74M HKD | 18.43M HKD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.